News Sentiment

CRDF sentiment intelligence

Cardiff Oncology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.88 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-33.8% over one week, -27.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Cardiff Oncology (CRDF) Proxy filing Summary

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction -33.8% Price reacting lower
Trend fit Trend inactive -27.3% over four weeks
Fair value -65.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 36
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 10
TradingView 8
simplywall.st 4
Investing.com 3
GlobeNewswire 3
Finviz 3
www.marketscreener.com 3

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 14
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Quartr Direct company coverage

Cardiff Oncology (CRDF) Proxy filing Summary

Cardiff Oncology (CRDF) has scheduled its annual meeting for June 11, 2026, where shareholders will vote on four key proposals: the election of six directors, the ratification of BDO USA, P.C. as auditor, an amendment to increase shares under the 2021 Equity Incentive Plan, and a

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 07:12
Source
Quartr
Stock Titan Direct company coverage

Cardiff Oncology (CRDF) CEO adds common shares and new warrants stake

Cardiff Oncology (CRDF) CEO Mani Mohindru purchased 34,364 common shares on July 14, 2026, at $1.455 per share and acquired an equal number of common stock purchase warrants. These transactions increased her direct holdings to 59,067 common shares and 34,364 warrants. The warrant

Tone
Positive 76/100
Event
Deals and strategy
Published
16 Jul 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Cardiff Oncology (CRDF) director buys 687,285 shares and warrants

Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases of 687,285 shares of common stock at $1.455 per share and an equal number of common stock purchase warrants with an exercise price of $1.33 per share, dated July 14, 2026. Following these transactions, Pa

Tone
Positive 74/100
Event
Market update
Published
16 Jul 2026 20:09
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Cardiff Oncology Inc For: 16 July By Investing.com

This article provides a Form 4 filing for Cardiff Oncology Inc. for July 16, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by an insider. The ar

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 20:09
Source
Investing.com Canada
AllSci Direct company coverage

Cardiff Oncology Raises $10M for Onvansertib Regulatory Push

Cardiff Oncology (CRDF) has raised $10 million in a registered direct offering to support regulatory discussions for its lead drug, onvansertib. The drug, an oral PLK1 inhibitor, showed promising Phase II results for RAS-mutated metastatic colorectal cancer, achieving a 72.2% obj

Tone
Positive 63/100
Event
Earnings
Published
16 Jul 2026 17:09
Source
AllSci
TradingView Direct company coverage

Cardiff Oncology Raises $10.05 Million in Registered Offering; Engages H.C. Wainwright

Cardiff Oncology successfully completed a registered equity financing, raising approximately $10.05 million in gross proceeds through the sale of shares and warrants to institutional investors and insiders. The company also engaged H.C. Wainwright as its exclusive placement agent

Tone
Positive 66/100
Event
Market update
Published
16 Jul 2026 12:40
Source
TradingView
Stock Titan Direct company coverage

Cardiff Oncology (Nasdaq: CRDF) closes $10.05M direct offering

Cardiff Oncology (Nasdaq: CRDF) has successfully closed a direct offering totaling approximately $10.05 million. The offering involved the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 per share and warrant, with certain officers and directors also p

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 12:40
Source
Stock Titan
Stock Titan Direct company coverage

Cardiff Oncology (NASDAQ: CRDF) prices $10.05M share and warrant financing

Cardiff Oncology Inc. (NASDAQ: CRDF) has priced a public offering to raise $10.05 million through the sale of common stock and accompanying warrants. The offering includes 9,293,078 shares of common stock and warrants to purchase an equal number of shares, with proceeds designate

Tone
Negative 37/100
Event
Market update
Published
16 Jul 2026 12:40
Source
Stock Titan
GlobeNewswire Direct company coverage

Cardiff Oncology Announces $10 Million Registered Direct Offering

Cardiff Oncology, Inc. has announced a registered direct offering expected to raise approximately $10 million. The offering includes the sale of common stock and accompanying warrants to both institutional investors and certain officers and directors of the company. The net proce

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 04:09
Source
GlobeNewswire
Moomoo Direct company coverage

Cardiff Oncology to Raise $10 Million in Share, Warrant Sale

Cardiff Oncology plans to raise $10 million through the sale of shares and warrants to Armistice Capital Master Fund. The company will sell 10 million shares of common stock and warrants to purchase up to 10 million shares at a price of $1.00 per share and accompanying warrant. T

Tone
Positive 68/100
Event
Market update
Published
16 Jul 2026 02:40
Source
Moomoo
Market source Direct company coverage

Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital

Cardiff Oncology announced a $10 million registered direct offering to bolster its working capital and general corporate purposes. The offering includes common stock and warrants, with participation from company officers and directors. The capital infusion will support the contin

Tone
Positive 60/100
Event
Market update
Published
15 Jul 2026 14:54
Source
Market source
MSN Direct company coverage

Cardiff Oncology announces $10M direct offering

Cardiff Oncology has announced a $10 million registered direct offering. The offering is priced at a premium to the preceding 5-day average closing price of its common stock. This financial move aims to raise capital for the company.

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 12:12
Source
MSN
Investing.com Direct company coverage

Cardiff Oncology prices $10M registered direct offering

Cardiff Oncology (NASDAQ:CRDF) announced a $10 million registered direct offering, selling over 8.5 million shares and accompanying warrants at $1.05 per share and warrant. Company officers and directors are participating in the offering. The biotech firm plans to use the net pro

Tone
Negative 38/100
Event
Market update
Published
15 Jul 2026 12:12
Source
Investing.com
Stock Titan Direct company coverage

Cardiff Oncology Seeks $10M as Some Officers and Directors Agree to Buy Shares

Cardiff Oncology (Nasdaq: CRDF) announced a registered direct offering to raise approximately $10 million by selling 8,571,429 common shares and accompanying warrants at $1.05 per share. Separately, certain officers and directors will purchase 731,707 shares and warrants at $1.43

Tone
Negative 32/100
Event
Market update
Published
15 Jul 2026 12:12
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBIT forward of Cardiff Oncology, Inc. – FWB:XE7C

The article provides a financial overview of Cardiff Oncology, Inc. (XE7C) on the Frankfurt Stock Exchange, specifically focusing on its enterprise value to EBIT forward ratio. It appears to be a stub or placeholder from TradingView, indicating where this financial metric would b

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 19:39
Source
TradingView
Quartr Direct company coverage

Cardiff Oncology (CRDF) Noble Capital Markets Emerging Growth Virtual Investor Conference summary

Cardiff Oncology (CRDF) summarized their Noble Capital Markets Emerging Growth Virtual Investor Conference, highlighting the promising clinical data for Onvansertib, an oral PLK1 inhibitor, in RAS-mutated metastatic colorectal cancer. The drug showed significant efficacy and tole

Tone
Positive 73/100
Event
Market update
Published
08 Jul 2026 14:09
Source
Quartr
TradingView Direct company coverage

Price to earnings forward of Cardiff Oncology, Inc. – NASDAQ:CRDF

This article provides access to the "Price to earnings forward" data for Cardiff Oncology, Inc. (NASDAQ: CRDF) on the TradingView platform. It highlights that the market was closed with no trades recorded at the time of viewing. The content primarily focuses on navigating to the

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 01:13
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C

The article displays the "Price to earnings forward" metric for Cardiff Oncology, Inc. (TRADEGATE:XE7C) on the TradingView platform. It indicates that the market was closed and no trades had occurred for this particular stock. The content primarily focuses on the financial data d

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 09:12
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C

This article provides financial information for Cardiff Oncology, Inc. (XE7C) on the Tradegate Exchange, specifically focusing on its enterprise value to EBIT forward. The content is presented through TradingView, a platform offering market data and financial tools. It indicates

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 13:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Cardiff Oncology, Inc. – NASDAQ:CRDF

This page provides the "Price to book forward" financial metric for Cardiff Oncology, Inc. (NASDAQ: CRDF). It states the period, value, and change for this specific financial data point. The content appears to be a data-only entry from TradingView, without additional analytical t

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 14:12
Source
TradingView
Finviz Direct company coverage

CRDF - Cardiff Oncology Inc Dividends

This article provides a detailed financial overview of Cardiff Oncology Inc. (CRDF), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 00:12
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Cardiff Oncology, Inc. – NASDAQ:CRDF

This article displays the "Price to sales forward" metric for Cardiff Oncology, Inc. (NASDAQ: CRDF). It is part of a financial data overview provided by TradingView. The content is primarily a data placeholder, indicating the company's ticker symbol and the market it trades on.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 00:10
Source
TradingView
Finviz Direct company coverage

CRDF,ANIP Dividends

This article provides key financial data for two companies, Cardiff Oncology Inc. (CRDF) and ANI Pharmaceuticals Inc. (ANIP), focusing on their stock performance, market capitalization, income, sales, and various financial ratios. It details current stock prices, recent changes,

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 17:10
Source
Finviz
Finviz Direct company coverage

CRDF - Cardiff Oncology Inc Latest SEC Filings

This article provides the latest SEC filings and a comprehensive financial overview for Cardiff Oncology Inc. (CRDF). It includes key financial metrics such as market cap, enterprise value, income, sales, various ratios, and performance indicators, alongside insider ownership and

Tone
Negative 39/100
Event
Market update
Published
04 Jul 2026 01:10
Source
Finviz
www.marketscreener.com Direct company coverage

Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000 Index

Cardiff Oncology, Inc. (NasdaqCM: CRDF) has been removed from the Russell 3000 Index, along with several other Russell indices including the Russell Small Cap Comp Growth, Russell 2500 Growth, and Russell 2000 Value benchmarks. The company is a clinical-stage biotechnology firm f

Tone
Negative 28/100
Event
Market update
Published
29 Jun 2026 10:39
Source
www.marketscreener.com